- Home
- BIOA vs CHRS Comparison
BIOA vs CHRS Comparison
Compare BIOA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- CHRS
- Stock Information
- Founded
- BIOA 2015
- CHRS 2010
- Country
- BIOA United States
- CHRS United States
- Employees
- BIOA N/A
- CHRS N/A
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIOA Health Care
- CHRS Health Care
- Exchange
- BIOA Nasdaq
- CHRS Nasdaq
- Market Cap
- BIOA 175.7M
- CHRS 194.1M
- IPO Year
- BIOA 2024
- CHRS 2014
- Fundamental
- Price
- BIOA $8.00
- CHRS $1.67
- Analyst Decision
- BIOA Hold
- CHRS Strong Buy
- Analyst Count
- BIOA 4
- CHRS 4
- Target Price
- BIOA $7.33
- CHRS $4.51
- AVG Volume (30 Days)
- BIOA 548.4K
- CHRS 1.1M
- Earning Date
- BIOA 11-06-2025
- CHRS 11-07-2025
- Dividend Yield
- BIOA N/A
- CHRS N/A
- EPS Growth
- BIOA N/A
- CHRS N/A
- EPS
- BIOA N/A
- CHRS 1.55
- Revenue
- BIOA $3,863,000.00
- CHRS $272,209,000.00
- Revenue This Year
- BIOA N/A
- CHRS N/A
- Revenue Next Year
- BIOA N/A
- CHRS $109.48
- P/E Ratio
- BIOA N/A
- CHRS $1.07
- Revenue Growth
- BIOA N/A
- CHRS 52.33
- 52 Week Low
- BIOA $2.88
- CHRS $0.66
- 52 Week High
- BIOA $25.33
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- BIOA 80.25
- CHRS 54.13
- Support Level
- BIOA $5.05
- CHRS $1.64
- Resistance Level
- BIOA $5.52
- CHRS $1.82
- Average True Range (ATR)
- BIOA 0.33
- CHRS 0.11
- MACD
- BIOA 0.14
- CHRS -0.02
- Stochastic Oscillator
- BIOA 83.10
- CHRS 17.31
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.